Improved understanding of gastrointestinal stromal tumors biology as a step for developing new diagnostic and therapeutic schemes

Oncol Lett. 2021 May;21(5):417. doi: 10.3892/ol.2021.12678. Epub 2021 Mar 28.ABSTRACTA gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the human gastrointestinal tract, with an estimated incidence of 10-15 per 1 million per year. While preparing holistic care for patients with GIST diagnosis, scientists might face several difficulties - insufficient risk stratification, acquired or secondary resistance to imatinib, or the need for an exceptional therapy method associated with wild-type tumors. This review summarizes recent advances associated with GIST biology that might enhance diagnostic and therapeutic strategies. New molecules might be incorporated into risk stratification schemes due to their proven association with outcomes; however, further research is required. Therapies based on the significant role of angiogenesis, immunology, and neural origin in the GIST biology could become a valuable enhancement of currently implemented treatment schemes. Generating miRNA networks that would predict miRNA regulatory functions is a promising approach that might help in better selection of potential biomarkers and therapeutical targets in cancer, including GISTs.PMID:33841578 | PMC:PMC8020393 | DOI:10.3892/ol.2021.12678
Source: Oncology Letters - Category: Cancer & Oncology Authors: Source Type: research